0000000000660962

AUTHOR

Irene Zarra-ferro

0000-0003-0835-034x

showing 2 related works from this author

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

2019

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an importan…

intravitrealgenetic structuresBevacizumabmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceVitrectomyReviewvascular endothelial growth factor/antagonists &ampbevacizumabPharmacologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsRanibizumabinhibitorsVascular endothelial growth factor/antagonists & inhibitorsMedicineDistribution (pharmacology)Pharmacokineticsranibizumab030304 developmental biologyAflibercept0303 health sciencesbusiness.industryafliberceptvascular endothelial growth factor/antagonists & inhibitorsIntravitreal administrationMacular degenerationmedicine.diseaseBevacizumabAge-Related Macular Degeneration030221 ophthalmology & optometryRanibizumabbusinessAfliberceptIntravitrealpharmacokineticsmedicine.drug
researchProduct

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

2021

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In this context, there is consistent evidence which supports the use of therapeutic drug monitoring (TD…

medicine.medical_treatmentPopulationAripiprazolePharmaceutical ScienceContext (language use)ReviewPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinearipiprazolePharmacy and materia medicamedicineAntipsychoticsPaliperidoneeducationAntipsychoticPopulation pharmacokinetic modelspharmacogeneticseducation.field_of_studyRisperidonerisperidonemedicine.diagnostic_testbusiness.industryCYP2D6PaliperidoneRisperidoneLAIRS1-441antipsychoticsTherapeutic drug monitoringpopulation pharmacokinetic modelsPharmacogeneticsAripiprazolebusinesspaliperidone030217 neurology & neurosurgeryPharmacogeneticsmedicine.drug
researchProduct